Cargando…

Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center

Abemaciclib significantly improves invasive disease-free survival when combined with endocrine therapy in clinical high-risk patients with HR+/Her2− early breast cancer (eBC). The objective of the following study was to model how many patients with eBC would be available for adjuvant treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dannehl, Dominik, Volmer, Lea L., Weiss, Martin, Matovina, Sabine, Grischke, Eva-Maria, Oberlechner, Ernst, Seller, Anna, Walter, Christina B., Hahn, Markus, Engler, Tobias, Brucker, Sara Y., Hartkopf, Andreas D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951288/ https://www.ncbi.nlm.nih.gov/pubmed/35330381 http://dx.doi.org/10.3390/jpm12030382

Ejemplares similares

Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow
por: Volmer, Léa, et al.
Publicado: (2022)

Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers
por: Dannehl, Dominik, et al.
Publicado: (2023)

Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre
por: Matovina, Sabine, et al.
Publicado: (2022)

Recurrence Score(®) Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial
por: Dannehl, Dominik, et al.
Publicado: (2022)

The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers
por: Schäffler, Henning, et al.
Publicado: (2023)

Association between 21-gene-assay and detection of disseminated tumor cells in patients with early breast cancer: results from the IRMA trial
por: Volmer, Léa L., et al.
Publicado: (2023)

Evaluation of sonographic detectability of different markers within an in vitro simulation model of the axilla
por: Guergan, Selin, et al.
Publicado: (2021)

Microfluidic Isolation of Disseminated Tumor Cells from the Bone Marrow of Breast Cancer Patients
por: Volmer, Léa L., et al.
Publicado: (2023)

Tumor-Free Resection Margin Distance in the Surgical Treatment of Node-Negative Squamous Cell Cancer of the Vulva Has No Impact on Survival: Analysis of a Large Patient Cohort in a Tertiary Care Center
por: Taran, Florin Andrei, et al.
Publicado: (2023)

Are you treating ypN0 patient with adjuvant abemaciclib?
por: Toss, A., et al.
Publicado: (2023)

Lysine-urethane-based tissue adhesion for mastectomy—an approach to reducing the seroma rate?
por: Boeer, B., et al.
Publicado: (2020)

Abemaciclib for breast cancer
Publicado: (2020)

Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1
por: Toi, Masakazu, et al.
Publicado: (2022)

Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany
por: Walter, Vincent P., et al.
Publicado: (2020)

CLRM-05 FEASIBILITY OF EVALUATING ABEMACICLIB NEUROPHARMACOKINETICS OF DIFFUSE MIDLINE GLIOMA USING INTRATUMORAL MICRODIALYSIS
por: Dalmage, Mahalia, et al.
Publicado: (2022)

Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis
por: Nduom, Edjah K., et al.
Publicado: (2023)

TRLS-02. FEASIBILITY OF EVALUATING ABEMACICLIB NEUROPHARMACOKINETICS OF DIFFUSE MIDLINE GLIOMA USING INTRATUMORAL MICRODIALYSIS
por: Jackson, Sadhana, et al.
Publicado: (2023)

A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy
por: Carter, Mary E., et al.
Publicado: (2022)

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

Abemaciclib: A multi-functional radiation modifier
por: Naz, Sarwat, et al.
Publicado: (2019)

Profile of abemaciclib and its potential in the treatment of breast cancer
por: Martin, James M, et al.
Publicado: (2018)

Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
por: Omarini, Claudia, et al.
Publicado: (2020)

Abemaciclib/fulvestrant: Leucopenia and Covid-19: case report
Publicado: (2020)

Drug-Induced Eosinophilic Pneumonia as an Adverse Event of Abemaciclib
por: Mitarai, Yuki, et al.
Publicado: (2022)

Clinicoradiological course of abemaciclib-induced pneumonitis with histology findings
por: Okayasu, Kaori, et al.
Publicado: (2023)

An experimental study: the effect of S. boulardii on abemaciclib-induced diarrhea
por: CAKCAK, İbrahim Ethem, et al.
Publicado: (2022)

Sequencing for an interdisciplinary molecular tumor board in patients with advanced breast cancer: experiences from a case series
por: Walter, Christina, et al.
Publicado: (2020)

Advancing Cancer Therapy Predictions with Patient-Derived Organoid Models of Metastatic Breast Cancer
por: Önder, Cansu E., et al.
Publicado: (2023)

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy
por: Kaufman, Peter A., et al.
Publicado: (2019)

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
por: Torres-Guzmán, Raquel, et al.
Publicado: (2017)

Molecular docking and machine learning analysis of Abemaciclib in colon cancer
por: Liñares-Blanco, Jose, et al.
Publicado: (2020)

Efficacy of Abemaciclib in the Management of Refractory Metastatic Extramammary Paget’s Disease
por: Takahashi, Gary W, et al.
Publicado: (2022)

Pharmacokinetic study on the co-administration of abemaciclib and astragaloside IV in rats
por: Sun, Sen, et al.
Publicado: (2022)

Abemaciclib does not increase the corrected QT interval in healthy participants
por: Chappell, Jill C., et al.
Publicado: (2023)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

Incidence, Prevalence, Hospitalization Rates, and Treatment Patterns in Myasthenia Gravis: A 10-Year Real-World Data Analysis of German Claims Data
por: Wartmann, Hannes, et al.
Publicado: (2023)

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
por: Johnston, Stephen R. D., et al.
Publicado: (2020)

Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments
por: Nawa, Hideki, et al.
Publicado: (2021)

Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib
por: Modi, Natansh D., et al.
Publicado: (2021)

Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure Treatment Continuation
por: Takada, Shinya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uit8fa3o50hen838eiigvqu3qv